Physician profile
Herbert Ausubel
NPI 1851304182
$1,072.99
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $116 · 2021: $466 · 2022: $91.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $261.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $246.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $154.49 | 2019-2021 | |
| Insmed, INC. | $121.34 | 2021 | |
| Nestle Healthcare Nutrition INC. | $46.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $26.68 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.14 | 2020 | |
| Redhill Biopharma INC. | $22.11 | 2020 | |
| Pfizer INC. | $21.56 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.56 | 2021 | |
| Allergan, INC. | $19.45 | 2020 | |
| Abbvie INC. | $19.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2022 | |
| Stemline Therapeutics INC. | $16.75 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Ausubel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.